Quick answers

What is Tirzepatide and what is it used for in research?
Tirzepatide is classified within the GLP-1 Metabolic group. Single-molecule dual agonist of GIP and GLP-1 receptors. Demonstrates greater A1c and body-weight reductions than GLP-1 alone. Research applications focus on the pathways outlined below. All references on this page describe published research only, Tirzepatide is supplied for in-vitro and laboratory use, not for human consumption.
How does Tirzepatide work?
Primary mechanism: Dual GIP/GLP-1 receptor agonist; superior weight-loss endpoints vs mono-agonism. Downstream effects depend on dose, timing, and the biological system under investigation. Receptor binding and post-receptor signalling for Tirzepatide remain areas of active study, and several proposed effects are supported only by preclinical data.
What is the typical Tirzepatide research dose?
Published research protocols for Tirzepatide describe per-dose ranges of 2.5–15 mg / week, with a weekly total near 2.5–15 mg, administered weekly sc. Typical cycle: titration: 4 weeks per step. These ranges reflect the literature and are not dosing recommendations for any individual.
Where can I buy Tirzepatide in Thailand?
Tirzepatide is supplied by Thailand Peptides, a Bangkok-based research-peptide supplier. Orders are placed directly via WhatsApp to the Bangkok research desk, no cart, no account, no forms. Pricing and shipping are provided on request. Open a line with the research desk →
How fast can Tirzepatide be delivered in Thailand?
Same-week delivery across Thailand is standard for orders confirmed within business hours (GMT+7, Monday–Saturday). Bangkok metro deliveries typically arrive within 1–3 business days; other provinces within 3–5. Regional Southeast Asia shipping is available on request.

What is Tirzepatide?

Tirzepatide is a research peptide in the GLP-1 Metabolic class. Dual GIP/GLP-1 receptor agonist; superior weight-loss endpoints vs mono-agonism. It is studied at per-dose ranges of 2.5–15 mg / week (2.5–15 mg weekly), administered weekly sc over cycles of titration: 4 weeks per step. Supplied in Thailand by Thailand Peptides, Bangkok-based, research use only.

Single-molecule dual agonist of GIP and GLP-1 receptors. Demonstrates greater A1c and body-weight reductions than GLP-1 alone.

Published and preclinical data are summarised below; dose ranges shown reflect protocols in the research literature and should be interpreted accordingly.

How does Tirzepatide work?

Tirzepatide is a single-molecule dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. Co-activation of both incretin receptors amplifies insulin secretion vs. GLP-1 alone; GIP activity at adipocytes contributes to greater body-weight reductions than GLP-1 monotherapy. Clinical head-to-head data (SURPASS-2) show larger A1c and weight reductions than semaglutide in type 2 diabetes.

Receptor binding affinity and post-receptor signalling for Tirzepatide remain areas of active investigation; several proposed effects within the GLP-1 Metabolic class are currently supported only by in-vitro or rodent data, and should be interpreted accordingly.

Tirzepatide pharmacokinetics

Half-life
Approximately 5 days, enabling once-weekly dosing.
Bioavailability
SC bioavailability ~80% across the clinical dose range in trials.
Route of administration
Subcutaneous injection via prefilled pen or research vial.
Metabolic clearance
Proteolytic degradation; no significant renal or hepatic accumulation reported in SURPASS data.

Tirzepatide research timeline

  1. 2021 Frías et al., SURPASS-2 shows superior glycaemic control vs. semaglutide in T2DM (N Engl J Med).
  2. 2022 Jastreboff et al., SURMOUNT-1 demonstrates up to ~21% weight loss in adults with obesity (N Engl J Med).

Tirzepatide dosage & protocol

Reference protocol for Tirzepatide (research context only, drawn from published literature):

  • Per dose: 2.5–15 mg / week
  • Weekly total: 2.5–15 mg
  • Frequency: Weekly SC
  • Cycle: Titration: 4 weeks per step

Tirzepatide injection & handling

Reconstitution
Clinical product supplied as prefilled autoinjector; research vials are reconstituted per lot specification.
Storage
Refrigerated at 2–8 °C; autoinjectors allow up to 21 days at room temperature after first use.
Sites used in the research literature
Subcutaneous abdomen, thigh, or upper arm; site rotation recommended.

Handling notes reflect methods used in published research protocols, not medical dosing guidance.

Order Tirzepatide
Ready to order? WhatsApp the Bangkok research desk, pricing and availability confirmed within the chat.
Ask about Tirzepatide ≥98% HPLC purity · supplier COA on file · Bangkok-based

Stacking Tirzepatide

Commonly referenced pairing with Tirzepatide: Monotherapy. Stacking rationale should be grounded in complementary mechanisms, not additive speculation; interactions at shared receptors or enzymatic pathways should be accounted for. Both compounds in a Tirzepatide stack are supplied by Thailand Peptides on the same order via the Bangkok research desk.

Contraindications

MTC / MEN-2, pancreatitis. Additional caution is warranted in individuals with hepatic or renal impairment, endocrine disorders, or concurrent pharmacotherapy affecting the pathways described above.

Further reading

Compare Tirzepatide with: Retatrutide Semaglutide

Citations

  1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024
  2. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. PMID: 34170647

References curated from PubMed. Additional literature summarised in the Thailand Peptides research library.